Merck Receives FDA Approval for ISENTRESS® (raltegravir) for Pediatric Oral Suspension

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) recently approved ISENTRESS® for oral suspension, a new pediatric formulation of Merck’s integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news